Total Funding
42
67
Total FundingCorporate Round raised
Growth Score 42 in past quarter
2 pts
Heat Score 67 in past quarter
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
200666
HaimBio is a drug development company. Their flagship product, Starvanip, is a metabolism-based cancer therapy.
- Hong-Yeoul Kim: Founder and CEO
About the Company
HaimBio is a drug development company. Their flagship product, Starvanip, is a metabolism-based cancer therapy that kills cancer cells by starving them of metabolic energy. Starvanip inhibits cancer cell growth and induces apoptosis -- the death of cancer cells. It does this by inhibiting the energy source of cancer cells, dramatically reducing
side effects such as harm to normal cells and reducing the toxicity of current anticancer therapies. The drug will also improve the rate of response and target a wider range of cancers. Tests have demonstrated efficacy with 12 types of cancer, as well as significant reductions of tumor sizes and increases of cancer cell death with almost no death of normal cells.